

Special Issue

Novel Delivery Systems and Engineering Technologies for Tumor Immunotherapy

Message from the Guest Editor

Tumor immunotherapy has revolutionized cancer treatment in recent years, achieving remarkable progress, particularly in areas such as immune checkpoint inhibitors (ICIs), CAR-T cell therapy, and cancer vaccines. However, low clinical response rates and immune-related adverse events (irAEs) remain major challenges in current immunotherapy approaches. These limitations largely stem from the complexity and heterogeneity of the tumor microenvironment (TME)—including mechanisms such as immunosuppressive cell infiltration, upregulation of checkpoint molecules, downregulation of antigen presentation molecules, and production of immunosuppressive factors. To address these challenges, researchers are developing various novel strategies to enhance the efficacy and safety of immunotherapy. Among these, novel immunotherapeutic agents and intelligent delivery systems show significant potential. These innovative systems enable in situ and targeted drug delivery, possess capabilities for multi-drug delivery and controlled release, and can remodel the tumor immune microenvironment, converting "cold" tumors into "hot" ones, thereby significantly improving immunotherapy efficiency.

Guest Editor

Dr. Qin Fan

Institute of Advanced Materials (IAM) and School of Materials Science and Engineering, Nanjing University of Posts & Telecommunications, Nanjing 210000, China

Deadline for manuscript submissions

30 June 2026



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/254874

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).